introduction tasmanian devil sarcophilus harrisii largest extant marsupial carnivore playing vital role maintaining diversity resilience tasmanian ecosystem specie currently listed endangered due devil facial tumour disease dftd contagious cancer spread biting social interaction dftd first observed tasmania however second transmissible cancer found giving rise naming convention dft1 first form dftd dft2 recent form mention dftd paper refer dft1 much written tasmanian devil immune system dftd interaction devil disease see comprehensive review currently treatment option dftd although research effort developing vaccine histocompatibility barrier different major histocompatibility complex class mhc-i molecule ordinarily prevent proliferation allograft tissue however dftd cell express mhc-i molecule able evade recognition host immune system .vaccine candidate focused upregulating expression mhc-i dftd cell using interferon gamma although successfully induced anti-dftd antibody within vaccinated individual sufficient prevent infection long term however unlike unvaccinated devil tumour vaccinated animal exhibited immune cell infiltration regressed immunotherapy drug candidate identified potential treatment dftd show promising anticancer activity vitro yet progressed clinical trial dftd cell sensitive receptor tyrosine kinase rtk inhibitor vitro particularly afatinib inhibits erbb2 receptor resulting suppression erbb3-stat3 axis erbb3-stat3 axis influence gene involved cell cycle angiogenesis overexpression linked cancer metastasis also enables dftd cell evade host immune system downregulating expression mhc-i molecule imiquimod guanosine analogue similarly suppresses element erbb3-stat3 axis well inducing dftd cell apoptosis via oxidative stress unfolded protein response upr recently statin atorvastatin also shown therapeutic potential dtfd atorvostatin disrupts cholesterol homeostasis important driver dftd addition atorvastatin prevented dftd cell proliferation vitro effect tasmanian devil fibroblast induced necrosis dftd xenograft nude mouse propose novel treatment dftd may derived cathelicidins major class vertebrate antimicrobial peptide cathelicidins small cationic peptide share conserved n-terminal preprosequence pleiotropic property extend beyond direct antimicrobial activity including chemotaxis wound healing angiogenesis cathelicidins also regulate cancer highly tissue specific manner type tumour overexpressed promote tumorigenesis others exhibit anticancer property example cathelicidin-bf bf-30 peptide venom banded krait bungarus fasciatus suppresses proliferation murine melanoma cell line b16f10 interfering transcription vasoendothelial growth factor vegf similarly bovine myeloid antimicrobial peptide bmap‑28 suppresses proliferation human thyroid cancer cell xenograft murine model caprine cathelicidin chmap-28 show selective cytotoxicity multiple human cell line vitro via necrotic mechanism multiple peptide derived porcine cathelicidin tritrpticin exhibit selective cytotoxicity towards jurkat cell leukemia line vitro via membranolytic mechanism cathelicidins isolated many vertebrate taxon however undergone gene expansion marsupial due need additional protection immunologically naïve young development pouch unlike eutherian marsupial born immunologically naïve develop mature immune response many month postpartum development within pouch young exposed diverse microbial flora pathogenic likely encouraged lineage-specific expansion cathelicidins marsupial resulting multiple diverse peptide cathelicidins identified four specie date including tasmanian devil many marsupial cathelicidins exhibited potent antimicrobial activity range microorganism vitro non-toxic mammalian cell line concentration µg/ml three devil cathelicidins antimicrobial activity saha-cath3 saha-cath3 haemolytic human red blood cell two moderately haemolytic high concentration μg/ml however anticancer potential yet explored investigate cytotoxicity seven tasmanian devil cathelicidins dft1 cell line vitro explore potential mechanism action using rnaseq aim identify peptide candidate future development anti-dftd therapeutic material method peptide preparation cell line tasmanian devil cathelicidin mature peptide saha-cath1 supplementary table synthesized chinapeptides co. ltd purity high performance liquid chromatograph hplc peptide solubilized water cell culture sigma-aldrich 0.01 glacial acetic acid concentration mg/ml serially diluted twofold roswell park memorial institute rpmi medium give final concentration mg/ml 31.25 μg/ml dft1 cell line derived primary dft1 tumour obtained menzies institute medical research university tasmania cell line maintained rpmi medium -glutamine gibco supplemented amniomax gibco heat-inactivated foetal bovine serum fbs penicillin/streptomycin sigma-aldrich t75 flask nunc cell passaged using trypsin–edta sigma-aldrich confluent cytotoxicity assay toxicity seven tasmanian devil cathelicidins dft1 cell determined twofold dilution 15.62 µg/ml four different timepoints confluent dft1 cell passage re-suspended rpmi fbs amniomax concentration cells/ml 100μl seeded well sterile flat-bottom well plate corning individual plate timepoint plate incubated prior cytotoxicity test peptide dilution added plate quadruplicate timepoints resulting final peptide concentration μg/ml μg/ml μg/ml 62.50 μg/ml 31.25 μg/ml 15.62 μg/ml ensure solvent affect absorbance value vehicle control also included maximum incubation period untreated growth control rpmi positive control dimethylsulfoxide dmso sterility control rpmi cell also included time point timepoint alamarblue immediately added well plate addition peptide remaining timepoints plate incubated additional addition peptide alamarblue added well timepoints addition alamarblue cell incubated resulting total peptide incubation period absorbance alamarblue timepoints determined biotek microplate reader cell viability calculated according manufacturer instruction expressed percentage cell survival compared untreated growth control one-sample one-tailed t-test used test significant difference viability treated cell negative growth control one sample two-tailed t-test also conducted ensure significant difference viability negative growth control cell treated solvent statistical analysis conducted development core team mechanism action rnaseq used characterize mechanism underlying anticancer activity peptide confluent dft1 cell passage number re-suspended concentration cells/ml seeded well sterile flat-bottom polystyrene 12-well plate corning following incubation medium aspirated cell replaced rpmi -glutamine fbs amniomax mg/ml peptide solution saha-cath1 added plate triplicate give final peptide concentration μg/ml highest concentration tested previous cytotoxicity assay hence would likely lead maximal peptide activity enabling precise analysis change gene expression vehicle control also added plate triplicate plate incubated incubation period selected cytotoxicity assay indicated sublethal peptide would maintain sufficient cell viability extract intact rna medium aspirated cell washed twice dulbecco phosphate buffered saline dpbs sigma-aldrich total rna extracted replicate peptide-treated vehicle control cell using rneasy mini kit qiagen cell lysis directly well well plate total rna quality assessed using rna nano kit agilent bioanalyzer sample displaying rin score total rna sample corresponding three treatment per peptide saha-cath1 vehicle control submitted ramaciotti centre genomics university new south wale sequencing illumina truseq mrna library prepared sample sequenced paired-end read across flowcell novaseq6000 resulted million raw read per sample raw read quality assessed using fastqc v0.11.8 quality length trimmed using trimmomatic v0.39 using default parameter trimmed read treatment control aligned tasmanian devil reference genome v7.0 ncbi gca_000189315.1 using star v2.7.8a alignment treatment summarized gene count using featurecounts subread package v1.5.1 gene count used input differential expression analysis gene count across sample removed analysis unlikely biologically relevant lacked sufficient statistical power firstly data normalized trimmed mean value tmm using edger v3.32.1 account composition bias library give effective library size downstream analysis multidimensional scaling used check variation treatment using limma v3.36.0 expression level normalized using upper-quartile normalization edaseq v2.24.0 account difference distribution lane sequencing depth differential expression analysis performed using voom limma v3.36.0 package treatment false discovery rate fdr cutoff 0.02 applied gene downregulated greater 1.5× fold selected gene ontology ingenuity pathway analysis ipa over-representation analysis biological process conducted clusterprofiler v3.18.1 statistical significance adjusted multiple comparison using benjamini–hochberg method term considered significant p-adj 0.05 remove general term gene set larger removed simplify function used remove redundant term pathway analysis conducted ipa qiagen using mammal specie type nervous system tissue/cell type result four tasmanian devil cathelicidins saha-cath3 significantly decreased cell viability compared growth control μg/ml saha-cath5 displayed rapid cytotoxic activity dft1 cell reduced cell viability time point p-value 3.63e−09 fig negative viability likely caused change medium incubation period cell viability calculated measuring amount reduced alamarblue calculation requires correction factor allow oxidized substrate present medium case low survival change medium treated cell medium used calculate correction factor result negative value saha-cath3 p-value 2.44e−06 saha-cath6 p-value 7.12e−05 required 18-h incubation period exhibiting similar level toxicity saha-cath5 saha-cath4 also significantly reduced cell viability p-value 0.04 slower acting requiring induce significant cytotoxicity figure change dft1 cell viability time peptide concentration µg/ml cell viability expressed percentage cell survival compared untreated growth control mean value error bar assay performed quadruplicate reported toxic peptide saha-cath3 saha-cath5 saha-cath6 reduced cell viability saha-cath4 reduced cell viability peptide saha-cath1 saha-cath2 saha-cath7 reduce cell viability full size image saha-cath3 also reduced cell viability lower concentration supplementary fig saha-cath5 cytotoxic concentration µg/ml p-value 5.56e−04 time point saha-cath6 cytotoxic concentration µg/ml incubation period p-value 1.05 e−04 saha-cath3 cytotoxic concentration 62.5 µg/ml incubation period p-value 1.12 e−04 exception saha-cath3 concentration 62.5 µg/ml mean cell viability 78.8 21.4sd although result statistically significant 0.07 differential expression analysis identified 12,402 gene total 15,548 across seven treatment compared control saha-cath5 treatment 74.05 toxic treatment genes—saha-cath3 12.63 saha-cath4 18.75 saha-cath6 15.56 dft1 cell treated non-toxic peptide saha-cath1 gene saha-cath7 quality filter chosen due low number differentially expressed gene treatment excluded analysis treatment dft1 cell saha-cath3 resulted downregulation gene involved dna replication cell cycle progression checkpoint table supported fig ipa analysis supplementary table canonical pathway significantly inhibited treatment peptide included cell cycle control chromosomal replication saha-cath4 p-value 9.64e−06 saha-cath5 p-value 1.85e−02 cyclins cell cycle regulation saha-cath3 p-value 3.27e−02 saha-cath4 p-value 1.22e−02 table gene sahacath3 treatment involved dna replication cell cycle progression full size table figure term downregulated sahacath3 treatment sahacath4 treatment sahacath5 treatment term associated cell cycle dna repair/checkpoints downregulated three saha-cath5 treatment term associated erbb yap1 signalling also downregulated full size image table gene involved immune cell activation upregulated saha-cath3 treatment full size table alongside cell cycle arrest saha-cath5 also regulated erbb hippo signaling pathway dft1 cell based analysis fig ipa also revealed canonical pathway enriched treatment hippo signaling p-value 1.64e−07 erbb p-value 9.14e−04 erbb2-erbb3 p-value 1.34e−03 erbb4 p-value 1.43e−04 supplementary table erbb3 gene significantly downregulated saha-cath5 0.34 fdr 9.99e−22 saha-cath6 induced endoplasmic reticulum stress dft1 cell via multiple mechanism according analysis fig ipa result confirmed element stress enriched saha-cath6 treatment significant canonical pathway enriched eif2 signaling p-value 1.33e−11 gadd34 ppp1r15a 2.14 fdr 2.15e−19 chop ddit3 1.91 fdr 1.03e−06 atf3 5.02 fdr 2.28e−16 upregulated supplementary table figure term upregulated downregulated saha-cath6 treatment term associated immune response upregulated treatment also indicated sign stress full size image interestingly saha-cath3 upregulated multiple gene involved cytokine expression immune signaling table analysis supported multiple immune process upregulated three treatment including angiogenesis wound healing immune cell differentiation cytokine response fig supplementary fig ipa analysis indicated canonical pathway th17 activation significantly enriched saha-cath3 p-value 6.55e−05 saha-cath4 p-value 3.17e−03 saha-cath6 p-value 2.55e−03 supplementary table discussion aimed identify cathelicidin candidate future development anti-dftd therapeutic four tasmanian devil cathelicidins saha-cath3 toxic dft1 cell high concentration saha-cath3 concentration 62.5 µg/ml saha-cath4 µg/ml saha-cath5 concentration µg/ml saha-cath6 concentration µg/ml previous study shown two peptide saha-cath3 non-toxic human cell line a549 two saha-cath5 reduced cell viability high concentration µg/ml resulting cell survival respectively concentration incubation period experiment saha-cath5 resulted cell survival fig interestingly fastest acting peptide also shown broad- spectrum antimicrobial activity one toxic peptide saha-cath4 previously shown antimicrobial activity vitro may indicate saha-cath4 also antimicrobial activity pathogen tested slower acting strain tested saha-cath3 induced cell cycle arrest g1/s phase cell cycle composed four phase dna replicated cell divided two cell progression one phase next primarily triggered cyclin dependent kinase cdks although cdks constantly expressed become activated upon binding specific cyclin subunit cyclin expression oscillates throughout four phase coordinate cell cycle transition phase triggered cyclins signifies point cell growth cease dna replication begin accompanied increase protein form pre-replication complex pre-rc required chromosomal replication orc1 cyclins element pre-rc overexpressed tumour identified potential therapeutic target many element downregulated dft1 cell treated saha-cath3 table aligns activity cathelicidins specie also suppress gene involved dna replication cell cycle progression data suggests saha-cath3 inducing cell cycle arrest g1/s phase explored potential therapeutic alongside cell cycle arrest saha-cath5 also regulated erbb hippo signaling pathway particularly interesting erbb3 gene significantly downregulated saha-cath5 receptor undergone copy gain dftd genome erbb-stat3 axis identified important driver dftd although dftd cell sensitive multiple rtk inhibitor appear respond acting via pathway suggests saha-cath5 may acting via similar mechanism oncogenic activity rtk signaling pathway often amplified formation positive feedback loop hippo pathway hippo pathway dysregulated transcription factor yap1 accumulates nucleus cause overexpression many gene involved proliferation survival wwc3 attenuates process phosphorylating yap1 prevent nuclear translocation wwc3 undergone hemizygous deletion dftd potentially resulting overexpression yap1 therefore high toxicity saha-cath5 dft1 cell may due peptide targeting synergistic activity rtk signalling yap1 expression rtk inhibition yet documented cathelicidins human cathelicidin ll-37 even shown opposite activating two rtks egfr erbb2 promoting tumour progression certain cell line however rtk inhibitor major class therapeutic wide variety cancer reveals important property saha-cath5 strong potential future drug development therapeutic dftd analysis saha-cath6 treatment suggested stress include glycosylation inhibition calcium depletion elevated reactive oxygen specie stress induced excessive misfolded protein start accumulate disrupt homeostasis unfolded protein response upr aim alleviate stress reducing protein translation increasing chaperone expression degrading malformed protein prolonged upr lead apoptosis enriched term saha-cath6-treated dft1 cell also indicated sign stress example protein hydroxylation downregulated suggesting attenuation function characteristic stress response increased mrna catabolism may indicative regulated ire1-dependent decay ridd process upregulated upr involves degrading mrna reduce burden term also suggested translation increased although may appear contradictory global translation reduced stress expression chaperone erad component upregulated one three main pathway activated upr attenuates global translation increasing expression protective protein two main pathway involved upr activated inositol-requiring enzyme 1-a ire1a activating transcription factor atf6 increased mrna catabolism treatment suggests ridd occurring may indicate activation ire1a evidence third pathway atf6 enriched however rna treatment degraded prior sequencing rin may influence result recommend study using lower concentration saha-cath6 confirm mechanism action ipa result suggests cytokine milieu within saha-cath3 6-treated dft1 cell encourages th17 differentiation mirroring activity vertebrate cathelicidins pro-inflammatory cytokine play paradoxical role cancer progression study indicated cathelicidin-induced inflammation promote development certain type tumour however many gene also shown contribute antitumour activity evidence interleukin-1 enhancing cytotoxic activity immune cell cancer transcription factor runx1 regulates expression gene inhibit leukaemia breast cancer cell research required determine dual role predominate dftd study identified four tasmanian devil cathelicidins saha-cath3 cytotoxic activity dft1 cell vitro using rnaseq show activity mediated via peptide-specific mechanism fig mechanism mirror activity therapeutic currently trialled dftd cell example saha-cath5 inhibited erbb-stat3 axis similarly afatinib imiquimod result also reveal three devil cathelicidins saha-cath may induce inflammatory pathway dft1 cell involving increase cytokine expression suggest future study validate pathway analysis using qrt-pcr peptide tested healthy devil cell recommend future study investigate effect cathelicidins fibroblast also suggest peptide tested human cancer cell line elucidate broader anti-cancer function establish selectivity peptide toxicity determine whether future potential drug development figure saha-cath3 induced cell cycle arrest g1/s phase saha-cath5 inhibited rtk signalling pathway yap1 expression saha-cath6 caused stress saha-cath3 activated inflammatory cytokine figure created biorender.com full size image